Alarice Cheng-Yi Lowe, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley · UCSF Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lowe’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A104353 · Current
Licensed to practise in California · since 2008 · expires 2028-05-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$98,429
Medicare paid this office $98,429 for 888 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Evaluation of fine needle aspirate with interpretation and report | 226 | $19,352 | $62 |
| Pathology examination of tissue using a microscope, intermediate complexity | 317 | $14,074 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 132 | $12,169 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 153 | $11,099 | $73 |
| Cell examination of specimen, selective cellular enhancement technique | 371 | $9,861 | $24 |
See all 19 services
| Evaluation of fine needle aspirate with interpretation and report | 226 | $19,352 | $62 |
| Pathology examination of tissue using a microscope, intermediate complexity | 317 | $14,074 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 132 | $12,169 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 153 | $11,099 | $73 |
| Cell examination of specimen, selective cellular enhancement technique | 371 | $9,861 | $24 |
| Special stained specimen slides to examine tissue, initial procedure | 159 | $5,201 | $31 |
| Evaluation of fine needle aspirate | 147 | $5,052 | $32 |
| Microscopic genetic analysis of tumor, manual | 62 | $3,114 | $37 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 19 | $2,840 | $149 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 31 | $1,977 | $64 |
| Pathology examination of tissue using a microscope, moderately high complexity | 17 | $1,763 | $73 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 60 | $1,743 | $20 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 25 | $1,267 | $34 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 13 | $1,031 | $79 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 13 | $964 | $57 |
| Pathology cytologic examination of specimen during surgery, initial site | 17 | $939 | $55 |
| Genetic sequencing localization, initial procedure | 23 | $920 | $38 |
| Cell examination of specimen, concentration technique | 32 | $666 | $20 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 18 | $548 | $30 |
Who their Medicare patients are
888 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 11% · Women 44% · Also on Medicaid 24% · Health risk score 1.84. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Cancer 46% · Diabetes 33% · Chronic kidney disease 32% · Coronary heart disease 31% · Atrial fibrillation 22% · Depression 19% · Heart failure 18% · COPD 17% · Stroke 13% · Dementia 9%.
The office billed $1,307,064, Medicare allowed $124,555 and paid $98,429; for 2,618 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 888 | 2,618 | 74 | 1.84 | $1,307,064 | $98,429 |
| 2023 | 883 | 2,557 | 74 | 1.58 | $1,374,383 | $115,207 |
| 2022 | 839 | 2,621 | 74 | 1.65 | $1,011,777 | $108,790 |
| 2021 | 829 | 3,755 | 74 | 1.62 | $1,033,523 | $148,193 |
| 2020 | 823 | 2,747 | 73 | 1.59 | $748,561 | $116,373 |
| 2019 | 445 | 1,153 | 72 | 1.93 | $234,524 | $42,917 |
| 2018 | 572 | 1,434 | 71 | 1.79 | $266,928 | $55,534 |
| 2017 | 667 | 1,632 | 71 | 1.75 | $283,734 | $59,403 |
| 2016 | 697 | 1,764 | 71 | 1.69 | $297,311 | $62,603 |
| 2015 | 618 | 1,669 | 71 | 1.79 | $279,421 | $60,134 |
| 2014 | 426 | 1,223 | 71 | 1.62 | $187,119 | $40,548 |
| 2013 | 755 | 2,159 | 71 | 1.58 | $356,825 | $78,787 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 24 services
| Evaluation of fine needle aspirate with interpretation and report | 197 | $17,325 | $63 |
| Pathology examination of tissue using a microscope, intermediate complexity | 284 | $14,065 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 177 | $12,915 | $72 |
| Special stained specimen slides to examine tissue, each additional procedure | 124 | $11,837 | $26 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 71 | $11,187 | $158 |
| Pathology examination of tissue using a microscope, moderately high complexity | 97 | $10,490 | $75 |
| Pathology examination of tissue using a microscope, high complexity | 36 | $5,962 | $130 |
| Cell examination of specimen, selective cellular enhancement technique | 212 | $5,501 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 150 | $5,008 | $31 |
| Evaluation of fine needle aspirate | 127 | $4,560 | $32 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 45 | $2,862 | $64 |
| Microscopic genetic analysis of tumor, manual | 51 | $2,621 | $38 |
| Pathology examination of specimen during surgery, first tissue block | 14 | $1,825 | $57 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 42 | $1,309 | $19 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 23 | $1,047 | $35 |
| Pathology cytologic examination of specimen during surgery, initial site | 16 | $968 | $57 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 11 | $956 | $80 |
| Genetic sequencing localization, initial procedure | 21 | $824 | $39 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 11 | $802 | $57 |
| Special stained specimen slides to identify organisms including interpretation and report | 14 | $746 | $24 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 12 | $374 | $29 |
| Cell examination of specimen, concentration technique | 17 | $347 | $20 |
| Special stained specimen slides to examine tissue including interpretation and report | 15 | $228 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 12 | $123 | $10 |
2022: 22 services
| Evaluation of fine needle aspirate with interpretation and report | 249 | $22,347 | $63 |
| Pathology examination of tissue using a microscope, intermediate complexity | 298 | $17,432 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 146 | $10,885 | $74 |
| Special stained specimen slides to examine tissue, each additional procedure | 109 | $9,511 | $26 |
| Pathology examination of tissue using a microscope, moderately high complexity | 54 | $7,381 | $76 |
| Evaluation of fine needle aspirate | 174 | $7,182 | $33 |
| Cell examination of specimen, selective cellular enhancement technique | 248 | $6,174 | $24 |
| Special stained specimen slides to examine tissue, initial procedure | 139 | $4,559 | $32 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 24 | $3,913 | $163 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 43 | $2,825 | $66 |
| Microscopic genetic analysis of tumor, manual | 52 | $2,733 | $38 |
| Pathology examination of tissue using a microscope, high complexity | 18 | $2,413 | $134 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 54 | $1,789 | $20 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 16 | $1,222 | $76 |
| Special stained specimen slides to identify organisms including interpretation and report | 18 | $1,147 | $24 |
| Genetic sequencing localization, initial procedure | 19 | $765 | $40 |
| Cell examination of body fluid, smears | 29 | $728 | $25 |
| Fine needle aspiration biopsy, first growth | 13 | $592 | $46 |
| Cell examination of specimen, concentration technique | 25 | $523 | $21 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 12 | $491 | $35 |
| Special stained specimen slides to examine tissue including interpretation and report | 13 | $256 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 13 | $52 | $4 |
2021: 22 services
| Pathology examination of tissue using a microscope, intermediate complexity | 394 | $38,637 | $35 |
| Evaluation of fine needle aspirate with interpretation and report | 290 | $25,584 | $66 |
| Special stained specimen slides to examine tissue, each additional procedure | 164 | $16,018 | $27 |
| Evaluation of fine needle aspirate | 225 | $10,018 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 127 | $9,790 | $77 |
| Pathology examination of tissue using a microscope, moderately high complexity | 48 | $7,923 | $78 |
| Cell examination of specimen, selective cellular enhancement technique | 264 | $7,499 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 209 | $7,315 | $33 |
| Microscopic genetic analysis of tumor, manual | 62 | $3,725 | $40 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 37 | $3,047 | $78 |
| Pathology examination of tissue using a microscope, high complexity | 19 | $2,961 | $135 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 31 | $2,055 | $64 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 52 | $1,634 | $21 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 17 | $1,551 | $60 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 15 | $1,226 | $82 |
| Special stained specimen slides to identify organisms including interpretation and report | 22 | $1,206 | $25 |
| Genetic sequencing localization, initial procedure | 26 | $1,109 | $41 |
| Fine needle aspiration biopsy, first growth | 19 | $952 | $50 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 11 | $504 | $36 |
| Cell examination of specimen, concentration technique | 21 | $469 | $21 |
| Special stained specimen slides to examine tissue including interpretation and report | 20 | $337 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 16 | $70 | $4 |
2020: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 349 | $27,448 | $36 |
| Evaluation of fine needle aspirate with interpretation and report | 305 | $26,274 | $68 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 146 | $11,539 | $76 |
| Special stained specimen slides to examine tissue, each additional procedure | 116 | $10,250 | $27 |
| Cell examination of specimen, selective cellular enhancement technique | 245 | $6,638 | $25 |
| Pathology examination of tissue using a microscope, moderately high complexity | 48 | $6,227 | $81 |
| Special stained specimen slides to examine tissue, initial procedure | 147 | $5,323 | $34 |
| Evaluation of fine needle aspirate | 133 | $5,122 | $35 |
| Microscopic genetic analysis of tumor, manual | 64 | $3,751 | $41 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 24 | $1,905 | $79 |
| Pathology examination of tissue using a microscope, high complexity | 12 | $1,709 | $142 |
| Special stained specimen slides to identify organisms including interpretation and report | 25 | $1,354 | $26 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 18 | $1,122 | $62 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 13 | $982 | $76 |
| Fine needle aspiration biopsy, first growth | 21 | $970 | $46 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 27 | $708 | $21 |
| Genetic sequencing localization, initial procedure | 15 | $632 | $42 |
| Cell examination of specimen, concentration technique | 12 | $325 | $22 |
2019: 15 services
| Pathology examination of tissue using a microscope, intermediate complexity | 172 | $9,563 | $34 |
| Evaluation of fine needle aspirate with interpretation and report | 76 | $6,714 | $64 |
| Pathology examination of tissue using a microscope, high complexity | 20 | $3,383 | $130 |
| Cell examination of specimen, selective cellular enhancement technique | 120 | $3,244 | $25 |
| Pathology examination of tissue using a microscope, moderately high complexity | 29 | $3,164 | $74 |
| Special stained specimen slides to examine tissue, each additional procedure | 42 | $2,757 | $26 |
| Cell examination of specimen, concentration technique | 128 | $2,657 | $19 |
| Special stained specimen slides to examine tissue, initial procedure | 67 | $2,422 | $32 |
| Pathology examination of specimen during surgery, first tissue block | 21 | $2,266 | $55 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 16 | $1,217 | $76 |
| Microscopic genetic analysis of tumor, manual | 16 | $1,118 | $39 |
| Special stained specimen slides to identify organisms including interpretation and report | 14 | $1,012 | $24 |
| Evaluation of fine needle aspirate | 24 | $829 | $33 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 14 | $477 | $34 |
| Pathology examination of tissue using a microscope, moderately low complexity | 13 | $141 | $10 |
2018: 16 services
| Pathology examination of tissue using a microscope, intermediate complexity | 190 | $11,648 | $34 |
| Pathology examination of specimen during surgery, first tissue block | 64 | $7,086 | $56 |
| Evaluation of fine needle aspirate with interpretation and report | 79 | $6,575 | $62 |
| Pathology examination of tissue using a microscope, moderately high complexity | 48 | $5,961 | $75 |
| Pathology examination of tissue using a microscope, high complexity | 29 | $4,234 | $132 |
| Special stained specimen slides to examine tissue, each additional procedure | 42 | $3,488 | $25 |
| Cell examination of specimen, concentration technique | 163 | $3,259 | $19 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 39 | $2,758 | $71 |
| Cell examination of specimen, selective cellular enhancement technique | 93 | $2,520 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 60 | $2,121 | $32 |
| Evaluation of fine needle aspirate | 30 | $1,327 | $32 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $1,019 | $24 |
| Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician | 17 | $612 | $36 |
| Pathology examination of specimen during surgery, each additional tissue block | 11 | $362 | $28 |
| Pap test | 14 | $314 | $22 |
| Pathology examination of tissue using a microscope, moderately low complexity | 22 | $270 | $10 |
2017: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 231 | $14,085 | $33 |
| Pathology examination of tissue using a microscope, moderately high complexity | 49 | $5,873 | $73 |
| Pathology examination of specimen during surgery, first tissue block | 62 | $5,767 | $55 |
| Evaluation of fine needle aspirate with interpretation and report | 72 | $5,629 | $57 |
| Special stained specimen slides to examine tissue, each additional procedure | 58 | $4,342 | $25 |
| Pathology examination of tissue using a microscope, high complexity | 27 | $4,046 | $131 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 53 | $3,774 | $71 |
| Cell examination of specimen, concentration technique | 175 | $3,441 | $18 |
| Special stained specimen slides to examine tissue, initial procedure | 77 | $2,606 | $31 |
| Cell examination of specimen, selective cellular enhancement technique | 87 | $2,245 | $23 |
| Evaluation of fine needle aspirate | 36 | $1,310 | $31 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $1,115 | $24 |
| Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician | 17 | $604 | $36 |
| Pathology examination of specimen during surgery, each additional tissue block | 16 | $577 | $27 |
| Pap test | 19 | $540 | $28 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 16 | $520 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 39 | $490 | $10 |
| Pathology examination of tissue using a microscope | 14 | $75 | $5 |
2016: 19 services
| Pathology examination of tissue using a microscope, intermediate complexity | 238 | $13,707 | $32 |
| Evaluation of fine needle aspirate with interpretation and report | 102 | $8,167 | $59 |
| Pathology examination of specimen during surgery, first tissue block | 65 | $6,355 | $54 |
| Pathology examination of tissue using a microscope, moderately high complexity | 60 | $6,141 | $72 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 62 | $4,396 | $71 |
| Special stained specimen slides to examine tissue, each additional procedure | 69 | $4,320 | $23 |
| Cell examination of specimen, concentration technique | 164 | $3,312 | $19 |
| Special stained specimen slides to examine tissue, initial procedure | 89 | $3,041 | $30 |
| Cell examination of specimen, selective cellular enhancement technique | 105 | $2,895 | $24 |
| Pathology examination of tissue using a microscope, high complexity | 19 | $2,570 | $128 |
| Evaluation of fine needle aspirate | 50 | $1,794 | $31 |
| Special stained specimen slides to identify organisms including interpretation and report | 24 | $1,309 | $23 |
| Pathology examination of specimen during surgery, each additional tissue block | 22 | $570 | $26 |
| Pathology examination of tissue using a microscope, moderately low complexity | 43 | $525 | $10 |
| Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician | 14 | $490 | $35 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 12 | $405 | $34 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 12 | $252 | $19 |
| Preparation of tissue for examination by removing any calcium present | 18 | $219 | $11 |
| Pathology examination of tissue using a microscope | 17 | $105 | $6 |
2015: 19 services
| Pathology examination of tissue using a microscope, intermediate complexity | 240 | $11,670 | $32 |
| Evaluation of fine needle aspirate with interpretation and report | 101 | $7,411 | $60 |
| Pathology examination of specimen during surgery, first tissue block | 59 | $7,262 | $54 |
| Pathology examination of tissue using a microscope, moderately high complexity | 60 | $6,517 | $72 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 58 | $4,140 | $71 |
| Cell examination of specimen, concentration technique | 161 | $3,349 | $19 |
| Special stained specimen slides to examine tissue, each additional procedure | 61 | $3,124 | $18 |
| Pathology examination of tissue using a microscope, high complexity | 20 | $3,032 | $126 |
| Special stained specimen slides to examine tissue, initial procedure | 85 | $2,880 | $30 |
| Cell examination of specimen, selective cellular enhancement technique | 87 | $2,534 | $24 |
| Microscopic genetic analysis of tumor, manual | 16 | $1,700 | $46 |
| Evaluation of fine needle aspirate | 49 | $1,675 | $31 |
| Special stained specimen slides to identify organisms including interpretation and report | 23 | $1,110 | $23 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 13 | $381 | $19 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 11 | $366 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 26 | $301 | $10 |
| Pap test | 11 | $280 | $25 |
| Preparation of tissue for examination by removing any calcium present | 20 | $255 | $11 |
| X-ray of surgical specimen | 13 | $94 | $7 |
2014: 14 services
| Pathology examination of tissue using a microscope, intermediate complexity | 190 | $8,825 | $32 |
| Evaluation of fine needle aspirate with interpretation and report | 87 | $5,692 | $59 |
| Pathology examination of tissue using a microscope, moderately high complexity | 39 | $4,033 | $70 |
| Pathology examination of tissue using a microscope, high complexity | 22 | $3,076 | $123 |
| Cell examination of specimen, selective cellular enhancement technique | 97 | $2,448 | $23 |
| Pathology examination of specimen during surgery, first tissue block | 26 | $2,184 | $52 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 30 | $2,177 | $70 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 79 | $2,075 | $25 |
| Cell examination of specimen, concentration technique | 92 | $1,998 | $19 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 59 | $1,698 | $10 |
| Evaluation of fine needle aspirate | 44 | $1,378 | $30 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $796 | $23 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 12 | $294 | $18 |
| Pathology examination of tissue using a microscope, moderately low complexity | 18 | $179 | $9 |
2013: 15 services
| Special stained specimen slides to examine tissue, initial procedure | 115 | $16,082 | $35 |
| Pathology examination of tissue using a microscope, intermediate complexity | 348 | $15,679 | $30 |
| Evaluation of fine needle aspirate with interpretation and report | 145 | $9,556 | $58 |
| Cell examination of specimen, selective cellular enhancement technique | 145 | $7,775 | $48 |
| Pathology examination of tissue using a microscope, moderately high complexity | 56 | $5,443 | $68 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 77 | $5,215 | $68 |
| Pathology examination of specimen during surgery, first tissue block | 40 | $4,274 | $51 |
| Cell examination of specimen, concentration technique | 191 | $3,608 | $18 |
| Pathology examination of tissue using a microscope, high complexity | 24 | $3,010 | $120 |
| Evaluation of fine needle aspirate | 66 | $2,055 | $29 |
| Microscopic genetic analysis of tumor, manual | 19 | $1,687 | $43 |
| Special stained specimen slides to identify organisms including interpretation and report | 33 | $1,597 | $22 |
| Pathology examination of tissue using a microscope, moderately low complexity | 45 | $518 | $9 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 14 | $432 | $18 |
| Preparation of tissue for examination by removing any calcium present | 19 | $242 | $10 |
Medicaid work
$12,930 in 2024
Medicaid paid $12,930 for 423 billed services this clinician did in 2024, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 86 | $4,524 |
| TISSUE EXAM BY PATHOLOGIST | 151 | $4,335 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 130 | $2,569 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 26 | $930 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 17 | $401 |
| Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site | 13 | $171 |
| 2024 | 423 | 6 | 30 | $12,930 |
| 2023 | 241 | 3 | 34 | $6,680 |
| 2022 | 212 | 4 | 22 | $7,293 |
| 2021 | 345 | 6 | 28 | $8,742 |
| 2020 | 221 | 3 | 25 | $6,039 |
| 2019 | 49 | 2 | 17 | $1,255 |
| 2018 | 69 | 3 | 21 | $1,439 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 105 | $3,437 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 89 | $1,925 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 47 | $1,318 |
2022
| TISSUE EXAM BY PATHOLOGIST | 104 | $3,569 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 50 | $2,514 |
| Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site | 31 | $656 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 27 | $553 |
2021
| TISSUE EXAM BY PATHOLOGIST | 119 | $3,702 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 66 | $1,926 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 45 | $1,431 |
| Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site | 57 | $897 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 44 | $541 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 14 | $245 |
2020
| TISSUE EXAM BY PATHOLOGIST | 103 | $2,848 |
| CYTP EVAL FINE NEEDLE ASPIRATE INTERP & REPORT | 72 | $2,315 |
| Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal | 46 | $876 |
2019
| Pap test | 34 | $869 |
| TISSUE EXAM BY PATHOLOGIST | 15 | $386 |
2018
| Pap test | 40 | $924 |
| Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician | 14 | $359 |
| TISSUE EXAM BY PATHOLOGIST | 15 | $156 |
Money from drug and device companies
$21 in 2023
A payment is not proof that care is biased.
| Hologic Sales and Service | Panther Fusion | $21 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2023-03-17 | Panther Fusion | $21 |
Professional record
- NPI
- 1023250917
- Licence
- CA A104353, MA 249276California A104353: Current · expires 2028-05-31
- Trained
- University of California, San Diego School of Medicine, 2006
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZC0500X (207ZC0500X); Federal specialty code 207ZP0101X (207ZP0101X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-03-24
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 10833 Le Conte Ave, Los Angeles, CA, 90095